Mavacamten Showing Real-World Success in Treating oHCM
MANCHESTER — Mavacamten (Camzyos, Bristol Myers Squibb) continues to show promising results in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), a consultant cardiologist said at the recent British Cardiovascular Society Annual Conference 2025.
William Jenkins, a consultant cardiologist at the Royal Infirmary of Edinburgh, said that real world outcomes mirror those from clinical trials, including EXPLORER and VALOR-HCM.
High Rates of Symptom Improvement
Notably, data from three UK centres showed that about 70%-80% of patients experienced symptomatic improvement with mavacamten treatment. In addition, 90% saw a 30mmHg drop in the left ventricular outflow tract (LVOT) gradient – considered a significant reduction in obstruction.
William Jenkins
Although patients initially required 'very intense echocardiographic surveillance', Jenkins said 'it gets much easier' after the first few months of treatment.
'I think our reliance upon echocardiography will probably reduce as we get more experience with this,' he told Medscape News UK .
A First-in-Class Therapy
Mavacamten, a cardiac myosin inhibitor, is the first drug of its kind. It works by normalising contractility, reducing dynamic LVOT obstruction, and improving cardiac filling pressures in people with HCM.
'HCM is something that develops over decades,' Jenkins said. 'You can develop symptoms early, but you can have those symptoms for a really long time before you go on to develop other things like abnormal heart rhythms, heart failure, or dying suddenly.'
He added that although oHCM is considered rare, many patients could benefit from treatment.
Managing HCM still falls within general cardiology in some centres, Jenkins noted, raising concerns that patients may not be reviewed as frequently as needed.
'People live with it for years and years — if not decades — before they develop any of the end stage features of HCM,' Jenkins said. 'They can become very adapted to their symptoms.'
Patient Advocacy and Experience
Hypertrophic cardiomyopathy affects around 1 in 500 people in the UK and US, with about two thirds of cases involving obstruction.
Katharine McIntosh, head of research and policy at Cardiomyopathy UK, told Medscape News UK that mavacamten had been a 'cause for excitement' among patients. 'It's the first big cardiomyopathy-specific drug.'
McIntosh expressed frustration at the slow rollout of the drug, which was recommended for NHS use in England and Wales in 2023 and in Scotland in 2024.
'It's at the point now where one would have thought that everyone who should be on it would be getting onto it. But that's just not been the case,' she said.
A recent Cardiomyopathy UK survey found that patients who accessed mavacamten were 'very positive' about its effects. Respondents described it as 'life changing' and felt like they had been given their lives back, McIntosh said.
Challenges Facing Widespread Use
One barrier is that mavacamten must be prescribed and monitored by specialists experienced in treating cardiomyopathies – resources not available at all centres.
Prescribing guidance states that patients require echocardiography before and at regular intervals after starting treatment. Genetic testing for Cytochrome P450 (CYP) 2C19 (CYP2C19) is also needed to guide dosing.
Long-Term Outlook
Jenkins said that three key issues must be considered before prescribing mavacamten:
Close early monitoring is needed, as the drug can cause left ventricular systolic dysfunction.
CYP2C19-related drug interactions require pharmacy input.
Counselling is essential due to potential foetal toxicity risks.
'Most people tolerate this [drug] very well', he said. After the initial 12-week period, follow-up can be reduced to every 3-6 months.
'This is an indefinite medication for a lot of people' Jenkins said. However, with an estimated annual cost of almost £14,000 per patient, he stressed the need for careful initial use.
'Right now, the indication is for symptomatic, severe LVOT obstruction,' he said. However, 'there's no reason in the long-term why this shouldn't become first-line'.
Whether mavacamten offers benefit for oHCM patients without obstruction remains unclear.
Jenkins has acted as a consultant to BMS and AstraZeneca. McIntosh had no conflicts of interest to disclose.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Cytokinetics, Incorporated (CYTK) Price Target Lowered To $53 from $71 at JPMorgan
Cytokinetics, Incorporated (NASDAQ:CYTK) is one of the 13 Biotech Stocks with Huge Upside Potential. Tessa Romero, an analyst at JPMorgan, has maintained her Overweight rating on Cytokinetics, Incorporated (NASDAQ:CYTK) but reduced the firm's price objective from $71 to $53. A lab technician using a microscope to examine the biopharmaceutical company's molecules. Aficamten's revised revenue projections, which anticipate a slower launch trajectory, are the basis for the modification. The management's latest remarks, which reflect the Camzyos launch pace for obstructive hypertrophic cardiomyopathy (oHCM), are consistent with this reevaluation. According to JPMorgan, expectations for adoption will be significantly influenced by the final medicine label. Cytokinetics, Incorporated (NASDAQ:CYTK) experimental treatment for oHCM, Aficamten, is still a valuable tool with promising clinical outcomes. Although JPMorgan admits that the launch trajectory was slower than anticipated, the company is still confident in the drug's unique profile when compared to Camzyos, especially with regard to pharmacology, safety, and dosing flexibility. These qualities and corroborating evidence support JPMorgan's assessment of aficamten's acceptability. The lower price objective is not a reflection of a shift in opinion about the drug's strategic worth or efficacy, but rather of modified commercial ramp assumptions. It is a late-stage biopharmaceutical business that focuses on discovering, developing, and bringing to market first-in-class muscle activators and next-in-class muscle inhibitors as possible cures for fatal diseases where muscle function is impaired or deteriorating. While we acknowledge the potential of CYTK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Fast Company
2 hours ago
- Fast Company
Enough hype about AI in health—let's talk about results
There's no shortage of big promises about AI in healthcare. The U.S. government announced a $500 billion Stargate initiative to fund AI infrastructure, while the UK government announced £82.6 million in research funding for three projects, two of which are using AI to tackle cancer and Alzheimer's disease. But ask any patient waiting for a diagnosis, or a clinician searching for certainty, and the real question cuts through all the noise: When will all the innovation deliver real impact where it matters most? We've entered an era where healthcare data is measured in exabytes—genomes, images, clinical notes, labs, and signals from every continent. At SOPHiA GENETICS, we've just achieved the milestone of analyzing 2 million patient profiles. It's a number that was unimaginable a decade ago. Yet the value of data isn't in volume. It's what you do with it. Insight matters only if it changes an outcome, shortens a diagnostic odyssey, or opens up a new chance for a patient. It's time to move from conversation to action. Too often, insights get trapped in institutional silos or left in endless pilot projects, just out of reach of the people who need them. 3 ways AI is already transforming medicine Today, technology can connect, for example, a patient in São Paulo with expertise in Seoul, uncovering patterns invisible to the human eye. Here are several ways AI is helping now. 1. Improving diagnostic accuracy: AI algorithms, particularly those based on deep learning, have demonstrated remarkable accuracy in diagnosing diseases from medical images and test results. These systems are trained on vast datasets, allowing them to recognize patterns and anomalies that might be missed by the human eye. For example, in dermatology, AI systems trained on images of skin lesions have shown the ability to detect skin cancers, such as melanoma, with high levels of precision. 2. Enhancing cancer prevention: AI techniques can be used to screen individuals for genomic markers and develop personalized cancer risk prediction scores. This proactive approach can help screen younger patients for genomic predispositions, empowering them to make informed prevention decisions and proactively monitor their health. 3. Tailoring treatments to genomic profiles: One of the most significant applications of AI is in the field of genomics. AI can analyze vast genomic datasets to identify mutations and variations that might influence an individual's response to certain treatments. For example, our SOPHiA DDM product can identify specific genomic markers that are susceptible to targeted cancer therapies, increasing the efficacy of the treatment and minimizing the risk of adverse reactions, for a more effective and safer treatment plan for patients. To scale up these AI applications there are many regulatory and compliance barriers to overcome. This requires investment in data security, creating clear guidelines, data security measures, and ensuring clinicians are fully trained. Our goal should be to create a regulatory environment that fosters innovation while safeguarding patient data and promoting public trust. We must democratize this powerful data to enable more physicians, practices, and hospitals to incorporate AI into daily clinical use so that a greater number of patients can access data-driven medicine, not just a select few. My message for governments investing in AI is clear: Balance investing in future AI tools with validating existing solutions that have already been proven to improve patient outcomes. Build the bridges that turn breakthroughs into benefits, so that data-driven medicine becomes a reality for every patient.
Gizmodo
8 hours ago
- Gizmodo
These Are the Dogs Most Likely to Get Diarrhea
Researchers in the U.K. analyzed vet records from over two million dogs to uncover the messy truth about canine diarrhea. Speaking from personal experience; fewer things in the world are messier than a dog with the runs. New research out today reveals how often people will take their dog to the vet for a bout of diarrhea, as well as some potential factors that could raise a pup's risk of it, such as their breed. Scientists at the Royal Veterinary College in the U.K. conducted the study, which examined the vet records of several million dogs. They estimated that one in every 12 dogs experiences diarrhea serious enough to prompt a vet visit each year, with certain breeds, including German Shepherds, more likely to experience it. The study also suggests that dogs are often getting overprescribed antibiotics as a result. Much like their human owners, dogs commonly suffer from diarrhea, and the study's researchers wanted to better understand how often it's diagnosed in primary care vet clinics and how it's typically managed. To do so, they analyzed the (anonymous) medical records of more than two million U.K. dogs that visited vets in 2019. They also studied the characteristics of 1,835 randomly selected cases of confirmed diarrhea within this sample. They calculated that 8.18% of dogs are diagnosed with diarrhea by their primary vet in a given year. But this risk was higher for six breeds in particular compared to the average mixed breed dog: the Maltese, Miniature Poodle, Cavapoo, German Shepherd, and Yorkshire Terrier. Conversely, only two breeds—the Jack Russell Terrier and Chihuahua—had a lower risk of diarrhea. Dogs younger than three and older than nine were also more likely to be diagnosed with diarrhea compared to middle-aged dogs. About a third of the cases they studied involved blood in the stool, a sign of more serious illness; nearly half of all dogs studied also experienced vomiting. But most cases in general cleared up without too much trouble, with more than 80% only meriting a single trip to the vet. In other words, as is true with people, doggy diarrhea is usually miserable but short-lasting. 'Experiencing the dreaded doggy poonami is one of those events every dog owner fears. This new study shows that diarrhea events are very common in dogs but that owners should not panic—no matter how bad the deluge, most dogs will recover in a few days with good veterinary treatment,' said lead study researcher Dan O'Neill, an associate professor of companion animal epidemiology at the RVC, in a statement provided to Gizmodo. The findings might also provide some insights into the nature of doggy diarrhea. It's possible that the higher-risk breeds highlighted in the study are more genetically vulnerable to digestive problems, for instance. The researchers also found other factors tied to a higher diarrhea risk, such as scavenging (the tendency for a dog to try eating things off the ground or from other non-intentional sources). On the more worrying side, the findings indicate that antibiotics are getting overused in dogs as well as humans. Veterinary guidelines have long advised against using antibiotics for mild to moderate cases of diarrhea in dogs, the researchers note. These drugs are not only unlikely to speed up a dog's recovery, but can incidentally increase antibiotic resistance. Despite these guidelines, however, nearly 40% of the cases they studied were still treated with antibiotics. 'High antibiotic use within veterinary clinical management against years of recommendation to the contrary raises concerns about unnecessary antibiotic therapy for this condition,' the researchers wrote in their paper, published in PLOS ONE. Dogs deserve nothing but the best healthcare, of course. But for most cases of diarrhea, time and less intrusive measures like switching to blander foods (boiled chicken, white rice, etc.) are all you need to help your dog through their gastrointestinal ordeal.
